Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Denmark's Leo Pharma Delays IPO Plans Beyond 2026, CEO Says
Leo Pharma A/S is delaying plans for an initial public offering beyond 2026, pushing back a listing it had previously targeted for this year. The Danish drugmaker, which specializes in treatments for skin conditions, is “ready” for an…
Big Pharma's race to stop Alzheimer's before it starts
Carole Greig was working as a companion to women living with dementia when she began to experience problems with her own short-term memory. The 71-year-old former bank employee was herself diagnosed with Alzheimer's disease in 2023: a terrible…
Spyglass Pharma (NASDAQ:SGP) Stock Falls 10.1% - What's Next?
Shares of Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) traded down 10.1% during trading on Monday. The stock traded as low as $30.00 and last traded at $29.5510. 32,138 shares traded hands during trading, a decline of 70% from the average…
Urogen Pharma (NASDAQ:URGN) Shares Gap Down - What's Next?
Shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $26.18, but opened at $24.00. Urogen Pharma shares last traded at $25.5580, with a volume of 311,241 shares trading…
FY2026 EPS Estimate for Spyglass Pharma Decreased by Analyst
Spyglass Pharma, Inc. (NASDAQ:SGP - Free Report) - Analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for Spyglass Pharma in a research note issued on Thursday, November 12th. HC Wainwright analyst Y. Chen now…
Avalyn Pharma (NASDAQ:AVLN) Stock Gets Price Target Trim from Morgan Stanley
Avalyn Pharma (NASDAQ:AVLN - Get Free Report) had its price target dropped by equities researchers at Morgan Stanley from $57.00 to $53.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has an…
Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Barclays Analyst Says
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target upped by stock analysts at Barclays from $329.00 to $341.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an 'overweight' rating…
310,727 Royalty Pharma PLC $RPRX Shares Sold by Alps Advisors Inc.
Alps Advisors Inc. trimmed its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 98.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor…
Royalty Pharma PLC $RPRX Stock: Danske Bank A S Grows Position
Danske Bank A S grew its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 44.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 1,107,117 shares of the biopharmaceutical…
Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Sees Large Decrease in Short Interest
Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) was the target of a significant decrease in short interest in October. As of October 30th, there was short interest totaling 9,125 shares, a decrease of 49.8%…
Moonshot AI pivots Kimi models from coding to science as benchmark gains flatten
Because Moonshot AI sees diminishing returns in coding, the Beijing startup is redirecting its Kimi language models toward biology, chemistry, and pharma research. International director Giacomo Ficari said at the Web Summit in Lisbon that science…
Spyglass Pharma, Inc. (NASDAQ:SGP) Stock Rated 'Moderate Buy' by Wall Street Brokerages
Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) has been assigned an average rating of 'Moderate Buy' from the nine analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell…
FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever. The approval of Wilserdly, also known as…
Jim Cramer says J&J is a 'metaphor for what's working' in the stock market
Johnson & Johnson is a prime example of the kind of stock doing well in the broader market as investors shy away from the volatile artificial intelligence trade. '[J & J] is a metaphor for what's working,' Jim Cramer said Monday on CNBC, as shares…
In a win for MAHA, FDA creates new regulatory category for the supplement NAC
WASHINGTON – The Food and Drug Administration is proposing a new classification for a product that's existed in a legal grey area for years, a win for proponents of dietary supplements, including members of the MAHA movement. The proposed…
Receive a Daily briefing on Pharma Industry News
Get Started